文献速递临床试验与 GCP新药、器械与细胞基因治疗研发流行病学与生物统计

跳过2期试验削弱3期肿瘤药物试验的风险获益平衡

Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials.
PubMed 文献 · J Clin Epidemiol · 2023-04-05

该研究在ClinicalTrials.gov注册的2013至2019年主要完成日期之间的3期实体瘤试验中构建样本,尝试用严格和宽泛标准将每个3期试验与支持性2期试验匹配。129个3期试验组符合条件,近一半涉及2期跳过。2期跳过的3期试验在宽泛匹配标准下汇总疗效估计显著更差,在严格匹配标准下汇总疗效估计不显著更差;安全性结局未见显著差异。结论认为跳过2期的3期试验风险获益平衡不如有2期支持的试验。

要点

  • 129个3期实体瘤试验组中近一半涉及2期跳过。
  • 2期跳过的3期试验在宽泛匹配标准下汇总疗效估计显著更差。
  • 2期跳过的3期试验与未跳过的试验在安全性结局上未见显著差异。

核心结论

  • 跳过2期的3期试验风险获益平衡不如有2期支持的试验。

研究设计与样本

  • 研究构建了ClinicalTrials.gov注册的2013至2019年主要完成日期之间的3期实体瘤试验样本。
  • 研究尝试用严格和宽泛标准将每个3期试验与支持性2期试验匹配。
  • 3期结局采用随机效应模型进行Meta分析,并在跳过与未跳过2期的试验间进行亚组对比。
  • 129个3期试验组符合条件,近一半涉及2期跳过。

主要发现

  • 2期跳过的3期试验在宽泛匹配标准下汇总疗效估计显著更差。
  • 2期跳过的3期试验在严格匹配标准下汇总疗效估计不显著更差。
  • 2期跳过的3期试验与未跳过2期的3期试验在安全性结局上未见显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Drug developers sometimes launch phase 3 (P3) trials without supporting evidence from phase 2 (P2) trials. We call this practice "P2 bypass." The aims of this study were to estimate the prevalence of P2 bypass and to compare the safety and efficacy results for P3 trials that bypassed with those that did not. STUDY DESIGN AND SETTING: We created a sample of P3 solid tumor trials registered on ClinicalTrials.gov with primary completion dates between 2013 and 2019. We then attempted to match each with a supporting P2 trial using strict and broad criteria. P3 outcomes were meta-analyzed using a random effects model with subgroup contrast between trials that bypassed and those that did not. RESULTS: 129 P3 trial arms met eligibility and nearly half involved P2 bypass. P3 trials involving P2 bypass produced significantly and nonsignificantly worse pooled efficacy estimates using broad and strict matching criteria, respectively. We did not observe significant differences in safety outcomes between P3 trials that bypassed P2 and those that did not. CONCLUSION: The risk/benefit balance of P3 trials that bypassed P2 is less favourable than for trials supported by P2.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Moyer H, Bittlinger M, Nelson A, et al. Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials. J Clin Epidemiol. 2023. PMID: 37028684. doi:10.1016/j.jclinepi.2023.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。